Pfizer (PFE)

Why settle for puny yields when you can buy these monster dividend stocks?

Things are going from bad to worse for the pharmaceutical giant.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Take advantage of short-term weakness by stepping into the right long-term investments when they go on sale.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the

Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.

Don't wait until they recover to initiate positions.

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.

GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying the industrial equipment supplier aims to lift revenue above EUR 7 billion and raise its EBITDA marg

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion

Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

These dividend stocks could help make retiring on $500,000 a real possibility.

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.